title: Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14).
abstract: Lack of CD56 expression was reported to be associated with a poor prognosis in multiple myeloma (MM) patients treated with conventional chemotherapy. Aim of our retrospective study was to analyse whether CD56 expression on MM cells reveals as a prognostic factor in patients treated with high-dose chemotherapy. MM cells of 99 patients prior to treatment with high-dose chemotherapy were analysed for CD56 expression by flow cytometry. Multivariable analysis of event-free survival in these patients showed no statistically significant difference between the CD56(-) (n=28) and the CD56(+) (n=71) group. The lack of CD56 expression on MM cells of these patients correlated significantly with the presence of translocation (11;14) (t(11;14)) (estimated correlation coefficient=0.655 95%, confidence interval (0.481; 0.779)). In summary, our results indicate that lack of CD56 expression on MM cells is not a prognostic marker in patients treated with high-dose chemotherapy, but is associated with t(11;14).
authors: Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
authors: M
authors: M
authors: Hundemer
authors: U
authors: U
authors: Klein
authors: D
authors: D
authors: Hose
authors: M-S
authors: MS
authors: Raab
authors: F W
authors: FW
authors: Cremer
authors: A
authors: A
authors: Jauch
authors: A
authors: A
authors: Benner
authors: C
authors: C
authors: Heiss
authors: M
authors: M
authors: Moos
authors: A D
authors: AD
authors: Ho
authors: H
authors: H
authors: Goldschmidt
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers; D019002:CD56 Antigen / Q000235:genetics / Q000378:metabolism*; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D019653:Myeloablative Agonists / Q000008:administration & dosage*; D012189:Retrospective Studies; D014178:Translocation, Genetic / Q000235:genetics; D014182:Transplantation, Autologous
chemical_list: D015415:Biomarkers; D019002:CD56 Antigen; D019653:Myeloablative Agonists; D008558:Melphalan